Cas:877402-49-8 1-methoxy-3,4-dihydroisoquinoline manufacturer & supplier

Chemical Name:1-methoxy-3,4-dihydroisoquinoline

CAS.NO:877402-49-8

Synonyms:3,4-dihydro-1-methoxyisoquinoline

Molecular Formula:C₁₀H₁₁NO

Molecular Weight:161.20000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:21.59000

Exact Mass:161.08400

LogP:1.07130

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,4-dihydro-1-methoxyisoquinoline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,4-dihydro-1-methoxyisoquinoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,4-dihydro-1-methoxyisoquinoline Use and application,3,4-dihydro-1-methoxyisoquinoline technical grade,usp/ep/jp grade.

Related News: Bulk drug substances mainly include vitamins, antibiotics, hormones, antipyretics and analgesics, among which vitamin C, erythromycin thiocyanate, penicillin, azithromycin, and semi-synthetic cephalosporins are the most concentrated products in the industry in terms of production and overcapacity. 1-methoxy-3,4-dihydroisoquinoline manufacturer A key publication in a preclinical model demonstrated rigosertib��s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: ��A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.�� Cell 165, 643). 1-methoxy-3,4-dihydroisoquinoline supplier Bulk drug substances mainly include vitamins, antibiotics, hormones, antipyretics and analgesics, among which vitamin C, erythromycin thiocyanate, penicillin, azithromycin, and semi-synthetic cephalosporins are the most concentrated products in the industry in terms of production and overcapacity. 1-methoxy-3,4-dihydroisoquinoline vendor Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax president and CEO Stanley Erck said in a statement. “These clinical results reinforce that [the vaccine] is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. 1-methoxy-3,4-dihydroisoquinoline factory A key publication in a preclinical model demonstrated rigosertib��s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: ��A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.�� Cell 165, 643).